Rheumatology
| Rheumatoid Arthritis
Rheumatology
Rheumatoid Arthritis

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results

book_2 Source: ACR Convergence 2020 - Poster session - Abs #0208
calendar_today Published on Medfyle: November 2020
headphones 1 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • FINCH 1 assessed filgotinib efficacy and safety in patients with rheumatoid arthritis and inadequate response to methotrexate (MTX-IR).
  • Through Week 52, both filgotinib 100 and 200 mg showed sustained efficacy based on clinical and patient-reported outcomes and radiographic progression and appeared comparable to adalimumab.
  • Herpes zoster was observed in all treatment groups with a numeric increase in the filgotinib 200 mg group compared with adalimumab after Week 24.
  • Treatment with either dose of filgotinib was well tolerated in MTX-IR patients and no new safety signals were detected through Week 52.
Presenting Author
Read more arrow_downward Hide arrow_upward

Bernard Combe, MD, PhD
CHU Montpellier, Montpellier University
Montpellier
France

Presenter disclosures
Read more arrow_downward Hide arrow_upward

B. Combe, AbbVie, Janssen, Eli Lilly, Novartis, Gilead Sciences, Inc., Roche-Chugai, Sanofi, Pfizer, MSD, Bristol-Myers Squibb


Feedback